Tramadol hydrochloride solution
Disclosed herein is an analgesic solution for the treatment of pain comprising a pain-relieving effective amount of tramadol or a pharmaceutically acceptable salt thereof, a method of treating pain by administering said analgesic solution to a subject in need thereof, a kit that includes containers of the analgesic solution, and a dosing regimen for the analgesic solution.
1. An aqueous oral solution comprising:
(a) from about 4.5 mg/mL to about 5.5 mg/mL of tramadol hydrochloride as the sole active ingredient;
(b) from about 4% w/v to about 10% w/v of propylene glycol;
(c) from about 10% w/v to about 30% w/v of glycerin;
(d) a sufficient amount of a buffer to maintain the pH of the oral solution from about 4.5 to about 5.5;
(e) from about 0.01% w/v to about 0.2% w/v sucralose;
(f) a flavoring agent in an amount of from about 0.1% w/v to about 5% w/v;
(g) sodium benzoate in an amount of from about 0.1% w/v to about 1% w/v; and
(h) water,
wherein the solution is free or substantially free of polyethylene glycol.
2. An aqueous oral solution comprising:
(a) about 5 mg/mL of tramadol hydrochloride as the sole active ingredient;
(b) about 5% w/v of propylene glycol;
(c) about 20% w/v of glycerin;
(d) about 0.1% w/v of citric acid and about 0.2% w/v of trisodium citrate dihydrate;
(e) about 0.07% w/v of sucralose;
(f) a flavoring agent in an amount of from about 0.1% w/v to about 1% w/v;
(g) about 0.375% w/v of sodium benzoate; and
(h) water,
wherein (i) the solution has a pH of from about 4.5 to about 5.5 and (ii) the solution is free of polyethylene glycol.
3. The aqueous oral solution of claim 1 , wherein the solution has a pH of from about 4.8 to about 5.4.
4. The aqueous oral solution of claim 1 , wherein the solution has a pH of 5.0 or 5.1.
5. The aqueous oral solution of claim 2 , wherein the solution has a pH of from about 4.8 to about 5.4.
6. The aqueous oral solution of claim 2 , wherein the solution has a pH of 5.0 or 5.1.
7. The aqueous oral solution of claim 1 , wherein the amount of tramadol hydrochloride is about 5 mg/mL.
8. The aqueous oral solution of claim 1 , wherein the amount of propylene glycol ranges from about 5% w/v to about 7% w/v.
9. The aqueous oral solution of claim 1 , wherein the buffer is a citrate buffer.
10. The aqueous oral solution of claim 9 , wherein the citrate buffer is present in an amount of from about 0.2% w/v to about 0.4% w/v.
11. The aqueous oral solution of claim 1 , wherein the sucralose is present in an amount of about 0.1% w/v.
12. The aqueous oral solution of claim 1 , wherein the flavoring agent is grape flavor and present in an amount of from about 0.2% w/v to about 0.4% w/v.
13. The aqueous oral solution of claim 1 , wherein the sodium benzoate is present in an amount of from about 0.3% w/v to about 0.4% w/v.
14. The aqueous oral solution of claim 1 , wherein the solution exhibits an amount of tramadol hydrochloride of from about 0.45% w/v to about 0.55% w/v after storage at 25±2° C. and 40±5% relative humidity for 24 months.
15. The aqueous oral solution of claim 1 , wherein the solution exhibits an amount of tramadol hydrochloride of from about 0.48% w/v to about 0.53% w/v after storage at 25±2° C. and 40±5% relative humidity for 24 months.
16. The aqueous oral solution of claim 1 , wherein the solution exhibits an amount of tramadol hydrochloride of from about 0.49% w/v to about 0.51% w/v after storage at 25±2° C. and 40±5% relative humidity for 24 months.
17. The aqueous oral solution of claim 1 , wherein the solution exhibits a tramadol maximum plasma concentration (C max ) of from about 120 ng/mL to about 220 ng/mL and an 0-desmethyltramadol C max of from about 24 ng/mL to about 70 ng/mL following administration of the solution to an adult human under fasted conditions.
18. The aqueous oral solution of claim 1 , wherein the solution exhibits a tramadol area under the curve in a plot of analyte concentration in blood plasma versus time from zero to infinity (AUC 0-inf ) of from about 825 hr*ng/mL to about 2445 hr*ng/mL and an 0-desmethyltramadol AUC 0-inf of from about 370 hr*ng/mL to about 920 hr*ng/mL following administration of the solution to an adult human under fasted conditions; and wherein the solution is bioequivalent to an immediate release composition comprising tramadol when administered to an adult human under fasted conditions.
19. The aqueous oral solution of claim 1 , wherein the solution is free or substantially free of non-ionic surfactants and/or co-solvents.
20. A method of treating pain in a subject in need thereof, which comprises administering to the subject an effective amount of the aqueous oral solution of claim 1 .